SE0102856D0 - A new method - Google Patents
A new methodInfo
- Publication number
- SE0102856D0 SE0102856D0 SE0102856A SE0102856A SE0102856D0 SE 0102856 D0 SE0102856 D0 SE 0102856D0 SE 0102856 A SE0102856 A SE 0102856A SE 0102856 A SE0102856 A SE 0102856A SE 0102856 D0 SE0102856 D0 SE 0102856D0
- Authority
- SE
- Sweden
- Prior art keywords
- relates
- new method
- cyclodextrin
- active substance
- basic active
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Nanotechnology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0102856A SE0102856D0 (sv) | 2001-08-27 | 2001-08-27 | A new method |
| EP02760974A EP1423094A2 (en) | 2001-08-27 | 2002-08-26 | A new method |
| JP2003522444A JP2005503454A (ja) | 2001-08-27 | 2002-08-26 | 新規な方法 |
| PCT/SE2002/001519 WO2003017921A2 (en) | 2001-08-27 | 2002-08-26 | A method to improve complexation efficacy and produce high-energy cyclodextrin-complexes |
| US10/488,123 US20040242538A1 (en) | 2001-08-27 | 2002-08-26 | Method to improve complexation efficacy and produce high-energy cylodextrincomplexes |
| AU2002326275A AU2002326275A1 (en) | 2001-08-27 | 2002-08-26 | A method to improve complexation efficacy and produce high-energy cyclodextrin-complexes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0102856A SE0102856D0 (sv) | 2001-08-27 | 2001-08-27 | A new method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SE0102856D0 true SE0102856D0 (sv) | 2001-08-27 |
Family
ID=20285148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE0102856A SE0102856D0 (sv) | 2001-08-27 | 2001-08-27 | A new method |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20040242538A1 (sv) |
| EP (1) | EP1423094A2 (sv) |
| JP (1) | JP2005503454A (sv) |
| AU (1) | AU2002326275A1 (sv) |
| SE (1) | SE0102856D0 (sv) |
| WO (1) | WO2003017921A2 (sv) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006134877A1 (ja) * | 2005-06-13 | 2006-12-21 | Takeda Pharmaceutical Company Limited | 注射剤 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY106598A (en) * | 1988-08-31 | 1995-06-30 | Australian Commercial Res & Development Ltd | Compositions and methods for drug delivery and chromatography. |
| SE9702799D0 (sv) * | 1997-07-25 | 1997-07-25 | Astra Ab | New compounds |
-
2001
- 2001-08-27 SE SE0102856A patent/SE0102856D0/sv unknown
-
2002
- 2002-08-26 JP JP2003522444A patent/JP2005503454A/ja active Pending
- 2002-08-26 EP EP02760974A patent/EP1423094A2/en not_active Withdrawn
- 2002-08-26 WO PCT/SE2002/001519 patent/WO2003017921A2/en not_active Application Discontinuation
- 2002-08-26 US US10/488,123 patent/US20040242538A1/en not_active Abandoned
- 2002-08-26 AU AU2002326275A patent/AU2002326275A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003017921A3 (en) | 2003-11-13 |
| EP1423094A2 (en) | 2004-06-02 |
| US20040242538A1 (en) | 2004-12-02 |
| AU2002326275A1 (en) | 2003-03-10 |
| JP2005503454A (ja) | 2005-02-03 |
| WO2003017921A2 (en) | 2003-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE0100901D0 (sv) | New composition | |
| MXPA05002814A (es) | Formulacion para agentes lipofilicos. | |
| CY1108532T1 (el) | Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων | |
| CY1116464T1 (el) | Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης | |
| NO20062504L (no) | Sammensetninger og doseringsformer for forbedret absorpsjon | |
| ATE468332T1 (de) | Phenyl-(4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin- - yi)aminderivate | |
| BRPI0512108A (pt) | antibióticos contendo complexos de ácido borìnico e métodos de uso | |
| EP1145719A3 (en) | Use a ferrous salt for inhibiting oxidative degradation of pharmaceutical formulations | |
| AR032293A1 (es) | Estuche farmaceutico | |
| CY1106319T1 (el) | Τοπικη θepαπεια στη μασταλγια | |
| HK1068606A1 (en) | Novel aminobenzoephenones | |
| PT1121127E (pt) | Composicoes farmaceuticas orais contendo buprenorfina | |
| DE60102590D1 (de) | Darreichungsformen zur behandlung von oralen mykosen | |
| NO20023551D0 (no) | Ibuprofen-inneholdende aktivt middel-preparat | |
| NO331082B1 (no) | Formulering av kahalalid F, sett omfattende en slik formulering, samt rekonstituert losning derav og anvendelse av en fortynnet rekonstituert losning til fremstilling av et medikament for behandling av kreft | |
| DK1280558T3 (da) | Halvfast indgivelsesvehikel og farmaceutiske sammensætninger | |
| DE60101486D1 (de) | Verwendung von Polyaminosäurederivate als Konservierungsmittel | |
| TW200507838A (en) | Active substance combination comprising a 2,5-dihydroxybenzenesulfonic compound and a potassium ion channel modulator | |
| UY26171A1 (es) | Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía | |
| DE50114127D1 (de) | Torasemid enthaltende lagerstabile pharmazeutische zubereitungen | |
| SE0102856D0 (sv) | A new method | |
| DE50113974D1 (de) | Kombinationspräparate von 3-n-formylhydroxylaminopropylphosphonsäurederivaten oder 3-n-acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen | |
| AU2001285944A1 (en) | Fungicidal agent containing n-chlorotaurine and use thereof | |
| DK1273301T3 (da) | Farmaceutiske præparater baseret på aktive bestanddele der kan anvendes til ulovlig administration | |
| EP1603595A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRUG INDEPENDENCE |